Cellnovo Gets Early Foothold In US Diabetes Market With TypeZero Partnership
Executive Summary
Cellnovo's partnership with US start-up TypeZero Technologies and its participation in an upcoming international artificial pancreas trial will allow the company to gain an early foothold in the US market before seeking FDA clearance for its diabetes management system, said to be the first and only one of its kind to have an insulin patch pump with mobile connectivity features.
You may also be interested in...
Small-Cap Recap: Fiscal 2016 Spells Sea Change For Angle; Cellnovo; Novacyt; Nanobiotix
A status update on four startups working in the molecular diagnostics and radiotherapy sectors.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.